Chinese Herbal Formulation for Ulcerative Colitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Western medical treatments for inflammatory bowel disease (IBD), such as anti-inflammatory drugs and immune system suppressors, often lead to repeated relapses and adverse effects, and are insufficient in addressing the complexity of ulcerative colitis, which is associated with a higher risk of colon cancer progression.
Innovation Solution
A Chinese medicinal formulation comprising Radix Codonopsis (Dangshen), Rhizoma Atractylodis Macrocephalae (Bai Zhu), Sclerotium Poriae Cocos (Fu Ling), Rhizoma Zingiberis Officinalis (Gan Jiang), Radix Paeoniae Alba (Bai Shao), and Rhizoma Coptidis (Huanglian) is developed, which relieves Qi stagnation, disperses dampness, and addresses symptoms like diarrhea and colonic architectural distortion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional Western medical therapies (anti-inflammatory drugs, immune system suppressors) are used to treat inflammatory bowel disease, then the disease symptoms can be suppressed, but repeated relapses and adverse effects occur in nearly 50% of patients
Solution Approach 1:
The patent uses a composite herbal formulation containing multiple Chinese medicinal herbs (Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Sclerotium Poriae Cocos, Rhizoma Zingiberis Officinalis, Radix Paeoniae Alba, and Rhizoma Coptidis) working together in specific proportions. This composite approach addresses the limitations of single-agent Western therapies by combining multiple herbal components that work synergistically to reduce inflammation, regulate immunity, and minimize adverse effects while preventing relapses.
2Duration of action of stationary object
If long-term administration of Western medicines is used to treat IBD, then disease control can be maintained, but adverse effects increase and treatment complexity increases
Solution Approach 1:
The patent changes the therapeutic parameters by using a multi-component herbal formulation with specific weight ratios (12-22% Radix Codonopsis, 12-22% Rhizoma Atractylodis Macrocephalae, 30-40% Sclerotium Poriae Cocos, 7-17% Rhizoma Zingiberis Officinalis, 7-17% Radix Paeoniae Alba, and 1-11% Rhizoma Coptidis). This parameter optimization allows for long-term treatment with reduced adverse effects compared to conventional Western medicines.
3Ease of operation
If currently used Western treatments are applied to IBD patients, then some symptom relief can be achieved, but treatment effects are slow and colon cancer risk increases
Solution Approach 1:
The patent employs herbal components that work preliminarily to prevent disease progression and complications. The formulation includes herbs with preemptive actions against inflammation, immune dysregulation, and potential malignant transformation, addressing not only current symptoms but also preventing future complications like colon cancer while reducing treatment time.
Data Source
AI summary
This invention relates to a Chinese medicinal formulation for the treatment of inflammatory bowel diseases, and a method of preparation thereof. The formulation comprises herbal components selected from a group consisting of Radix Codonopsis (Dangshen), Rhizoma Atractylodis Macrocephalae (Bai Zhu), Sclerotium Poriae Cocos (Fu Ling), Rhizoma Zingiberis Officinalis (Gan Jiang), Radix Paeoniae Alba (Bai Shao) and Rhizoma Coptidis (Huanglian).